Theriva Biologics Valuation
| TOVX Stock | USD 1.47 0.15 9.26% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Theriva Biologics has a current Real Value of $23.69 per share. The regular price of the company is $1.47. Our model measures the value of Theriva Biologics from inspecting the company fundamentals such as Shares Outstanding of 2.78 M, return on equity of -0.59, and Shares Owned By Institutions of 21.20 % as well as reviewing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Theriva Biologics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Theriva Biologics is based on 3 months time horizon. Increasing Theriva Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Theriva Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Theriva Stock. However, Theriva Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.47 | Real 23.69 | Hype 1.46 |
The intrinsic value of Theriva Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Theriva Biologics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Theriva Biologics helps investors to forecast how Theriva stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Theriva Biologics more accurately as focusing exclusively on Theriva Biologics' fundamentals will not take into account other important factors: Theriva Biologics Total Value Analysis
Theriva Biologics is at this time anticipated to have valuation of (10.16 M) with market capitalization of 4.51 M, debt of 2.15 M, and cash on hands of 52.27 M. The negative valuation of Theriva Biologics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Theriva Biologics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(10.16 M) | 4.51 M | 2.15 M | 52.27 M |
Theriva Biologics Asset Utilization
One of the ways to look at asset utilization of Theriva is to check how much profit was generated for every dollar of assets it reports. Theriva Biologics has a negative utilization of assets of -0.25 %, losing $0.002498 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Theriva Biologics shows how discouraging it operates for each dollar spent on its assets.Theriva Biologics Ownership Allocation
Theriva Biologics has 10.48 % of its outstanding shares held by insiders and 21.2 % owned by institutional holders.Theriva Biologics Profitability Analysis
Net Loss for the year was (18.35 M) with profit before overhead, payroll, taxes, and interest of 0.About Theriva Biologics Valuation
Our relative valuation model uses a comparative analysis of Theriva Biologics. We calculate exposure to Theriva Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Theriva Biologics's related companies.Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. Theriva Biologics Inc. is headquartered in Rockville, Maryland. Theriva Biologics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 16 people.
Theriva Biologics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 644.3 K |
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.